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Presidential address: Back to the future of 
vascular surgery--Why certain procedures 
become obsolete 
John W. Hallett,  Jr., MD, Rochester, Minn. 
"So we beat on, boats against he current, borne back 
ceaselessly into the past." 
F. Scott Fitzgerald 
I am a full-time surgeon and a part-time sailor. 
But sailing has taught me that a complex blend of 
forces may change one's course to a destination: the 
currents, the tides, the weather, the rocks, the boat, 
and the crew. The sea has an unforgiving way of 
determining which methods of seamanship endure 
and which become obsolete. A sailor must know 
when to hold a steady course and when to change. 
Vascular surgery has been on a steady course for 
more than 40 years. Our basic operations have estab- 
lished superb long-term results, but the tides of tech- 
nology and the currents of managed care are chang- 
ing rapidly. The future of endovascular surgery has 
gripped our attention, while the lessons of the past 
slip quickly behind us. We seem captivated by new- 
ness. We sense that some common diagnostic tech- 
niques and surgical procedures may become obso- 
lete. For example, will contrast arteriography give 
way to spiral computed tomography? Will the ele- 
gance of carotid endarterectomy be edged aside by 
the expediency of carotid balloon angioplasty? These 
possibilities raise a certain level of excitement that 
comes with any technologic advance. 
They also stir another level of anxiety that such 
changes may not be the right thing for our patients 
or for us. How do we come to grips with changes in 
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vascular surgery? How do we personally deal with 
changes that either make us uncomfortable or do not 
seem right? Perhaps, it is just as important to under- 
stand how we can avoid the seduction of new proce- 
dures that appear beneficial on first glance but be- 
come calamitous with a longer look. The question is 
fundamental to either holding or changing the 
course of vascular surgery in the future: why do 
certain things in vascular surgery become obsolete? It 
is an intriguing question, and each of us has our own 
biases about the answers. Please indulge mine as you 
think about your own. 
As I consider my own instincts about this funda- 
mental dilemma, I inevitably find myself perusing the 
history of vascular surgery. 1 We must look back to 
know where we are going. Numerous examples of 
obsolescence r mind me that a complex blend of 
forces direct the changes.. 
I have selected seven forces that influence obso- 
lescence (Table I). They include (1) better under- 
standing ofpathogenesis; (2) improved materials and 
techniques; (3) less morbid and mortal approaches; 
(4) the ease to perform and to teach a technique; (5) 
the encouragement or obstruction of colleagues; (6) 
durability of the procedure; and (7) the cost. Finally, 
I will leave you with my thoughts about the ethics of 
change. This soul-searching will bring us back to the 
pivotal influence of change: the patient's best inter- 
est. 
Why is this blood vessel diseased? 
I know that treatments have changed and will 
continue to evolve as pathogenesis is clarified. Mo- 
lecular and cell iologists continue to elucidate the 
causes of  cardiovascular diseases. Their efforts must 
be supported and applied because basic research will 
generate new ideas in managing both occlusive and 
aneurysmal disease. 
History also reminds us that young investigators 
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Table I. Seven forces that influence 
obsolescence of any vascular procedure 
1. Better understanding ofpathogenesis 
2. Improved materials and techniques 
3. Less morbid and mortal approaches 
4. The ease to perform and to teach the technique 
5. Encouragement or obstruction of mentors 
6. Durability of the procedure 
7. Cost 
must be patient. They should be reminded that the 
revolution in modern vascular surgery that began 
after World War II had its biologic foundations laid 
decades earlier. Charles C. Guthrie of Chicago pub- 
lished his major study Blood Vessel Surgery and its 
Application in 1912. His colleague, Alexis Carrel, 
received the Nobel Prize in 1913 for his work on the 
suture of blood vessels and organ transplantation. 
Hopefully, current seminal contributions in basic re- 
search will receive quicker ecognition in the future. 
Although molecular and cell biology may overwhelm 
most surgeons, we must keep ourselves informed of 
the terminology and concepts (medical school never 
ends! ). 
Does the technology work? 
Those who fall to understand basic cell biology 
and the pathogenesis of vascular disease persist in 
trying technologies that are bound to fail. For me 
this premise remains one essential reason that many 
vascular technologies fade into obsolescence. One 
example from the past exemplifies the importance of 
a sound biologic basis for any surgical procedure. 
As an intern, I recall the Sparks mandril. 2 This 
silicone tube with its enveloping mesh was implanted 
in the subcutaneous thigh tissue of selected patients 
who had superficial femoral artery occlusion and 
clandication. The hypothesis was that local tissue 
would grow into the interstices of the surrounding 
synthetic mesh and create an "antogenized mesh 
graft." After several weeks, the silicone core tube 
could be mobilized via a surgical cutdown, and the in 
situ autogenized graft would be ready for a femoro- 
popliteal bypass. The engineer of this superficially 
clever idea did not understand that fibroblasts can 
only form a nonfunctional, stiff, collagenous tube 
and cannot replicate the simple elegance of an arterial 
wall with a functional adventitia, media, and endo- 
thelium. For years I kept an old Sparks mandril in my 
bottom desk drawer to remind me that technology 
without a sound biologic basis is history. 
Currently, some technologies for endovascular 
therapy may also be overlooking biologic reality. The 
endothelium hates too much heat or abrasion. 
Hence I was not surprised at the demise of the 
hot-tip laser or the abrasive atherectomy devices. The 
arterial wall also likes to move with each heart beat. 
This elasticity is essential to transferring arterial pres- 
sure distally and may be a fundamental stimulus for 
maintenance of normal vasomotor tone and endo- 
thelial function. Although stents may enhance arly 
patency after balloon angioplasty, they do not make 
long-term biologic sense. They may stretch the lu- 
men but leave the arterial segment fixed in a nonbio- 
logic rigidity. And will stents or other fastening de- 
vices that apply radial pressure on the arterial wall 
provide long-term secure attachment ofintraluminal 
grafts for aneurysms or occlusive disease? All engi- 
neers know that metal, especially under the stress of 
harmonic motion, fatigues and fractures with time. 
Stents remind me of Henry Petrosld's provocative 
book, To Engineer Is Human: The Role of Failure in 
Successful Design. aThose who are so enamored with 
implantable metallic devices and endovascular tech- 
niques might peruse Petroski's work. 
Does  it ma im or kill? 
I remember the morbidity and mortality that 
resulted from the first vascular operation that I saw as 
a medical student. An elderly man with claudication 
came to the hospital. His aortofemoral operation by 
the chief resident lasted 8 hours. He bled a lot! His 
graft thrombosed in the recovery room. His leg mus- 
cles swelled, and fasciotomies were required. His 
kidneys shut down. His other organs quit, and he 
died. Needless to say, I was not impressed that mod- 
ern vascular surgery was a pleasant or effective way to 
alleviate claudication. 
The chief resident rationalized the disastrous 
death by glibly saying, "That gomer just couldn't 
take a hit." In retrospect, hat patient's misfortune 
and that resident's arrogance have never left my 
memory. This formative xperience continues to in- 
fluence my current efforts to help patients without 
harming them. 
More than ever before, I find myself trying to fit 
the treatment to the patient and not vice versa. A 
mixture of tradition and obsolescence must continu- 
ally interact if I follow this philosophy. For example, 
I was reared on endarterectomy and bypass grafting 
as the optimal therapy for aortoiliac disease. I still feel 
strongly that the best long-term treatment for aor- 
toiliac atherosclerosis is the traditional aortofemoral 
bypass graft. This is the "Cadillac" treatment, but 
not every patient can drive or even needs a Cadillac. 
For more limited disease, I have learned that balloon 
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angioplasty is a good starting point. With more ex- 
tensive disease and other advanced medical comor- 
bidity, I have tended toward an axillofemoral bypass.. 
It may not be such a macho procedure, but it is more 
than enough intervention for some patients. 
A well-known visiting professor once admon- 
ished me that he only performs direct aortofemoral 
reconstructions, "Either the patient can take or not!" 
Such surgeons never accept hat a balance of tradi- 
tional surgery and newer, less-stressful therapies are 
in the patient's best interest. When appropriate, less- 
invasive therapy (e.g., balloon angioplasty) and bet- 
ter pain management (e.g., perioperative pidural 
analgesia) are in. Surgical machismo is out. 
Is it easy to perform? 
A common vascular procedure seldom gains 
widespread use or longevity unless a lot of physicians 
or surgeons can perform it with relative ease. The 
obvious corollary is that the technique must also be 
learnable by residents of varying technical abilities. In 
1979, my ~ mentor, Dr. R. Clement Darling, Sr., em- 
phasized this fundamental truth by several examples. 
The first was the rise of aortic bypass grafting over 
aortoiliac endarterectomy. Although endarterectomy 
was an elegant echnique and had excellent long- 
term patency rates for focal aortoiliac disease, the 
procedure was not as easy to learn as a bypass grafting 
procedure. Ergo, aortoiliac endarterectomy is practi- 
cally obsolete in 1996. 
The second example was in situ saphenous vein 
bypass grafting. Darling 4 had used the technique in 
the early 1960s when it was introduced by Karl 
Victor Hall s of Europe and Paul Cartier of Canada. 
In fact, I examined one of Darling's patients with an 
in situ graft that had been patent for 17 years. In my 
amazement, I asked him why he eventually aban- 
doned the method. His explanation was simple and 
direct. It was relatively easy for the novice surgeon to 
injure the valve cusp or the vein wall with the valvu- 
lotome. Consequently, it was safer and easier to 
teach residents to do a good reversed vein bypass 
graft. And because the majority of femoropopliteal 
bypass procedures were still being performed by gen- 
eral surgeons, he predicted that fewer veins and pa- 
tients would be hurt by reversed saphenous vein 
bypasses than the trickier in situ technique. Although 
the in situ method regained a foothold in the 1980s ,  6 
I wonder how many surgeons have taken the in situ 
journey and now revert to a "good ole" reversed 
saphenous vein whenever possible. 
Several other vascular procedures face the same 
difficulties of not being easy enough for all vascular 
specialists to learn and perform well. Angioscopy is 
one example. Despite the convincing work of Arnold 
Miller et al. 7 at Harvard, angioscopy has not gained 
wide acceptance. The equipment can be fickle, and 
the added benefits of its use are debatable. Likewise, 
I wonder about the resurgence of renal endarterec- 
tomy. It is my procedure of choice for bilateral prox- 
imal renal atherosclerosis. It is expeditious, anatomic, 
and durable, but it is a technique that many surgeons 
do not find as easy to learn as a bypass grafting 
procedure. Consequently, I predict hat renal endar- 
terectomy will remain relatively obsolescent com- 
pared with bypass grafts or balloon angioplasty. It is 
simply natural to do what is easier and safer in the 
hands of the majority of practitioners. 
Who is for it and who is against it? 
I will not spend much time on the politics of 
obsolescence, but it is real. Surgeons of the last 
generation recall the devotion of Rene Leriche to 
arterial resection and sympathectomy for occlusive 
disease. His influence in Europe was immense. Al- 
though the concept of vein grafting had been around 
since the early 20th century, Leriche did not embrace 
it. Despite his reticence, three of his fellows eventu- 
ally did progress to bypass grafting and endarterec- 
tomy for occlusive disease: DeBakey, dos Santos, and 
Kunlin. Smart fellows always seem to see beyond 
their mentor's devotion to obsolescent procedures. 
Is the procedure durable? 
I f  I have a passionate bias about any force that 
leads to obsolescence, it is the importance of durabil- 
ity. In the end, lack of durability has been the coup 
de grace for many vascular procedures. Almost any 
procedure will last 2 years, so adequate follow-up 
must extend toward 4 to 5 years. 
Consider some historic examples where poor du- 
rability became the impetus for obsolescence. Cadav- 
eric homografts for aortic aneurysm replacement 
looked good at first, but then tended to degenerate 
into aneurysms themselves. With time, nylon grafts 
also gave way to the durability of Dacron polyester. 
For occlusive disease, extensive thromboendarterec- 
tomy of the superficial femoral artery looked good at 
first, but did not have the staying power of a reversed 
saphenous vein graft. Synthetic grafts subsequently 
challenged vein for supremacy in the below-knee 
popliteal position, but lost when clinical trials with 
sufficient long-term follow-up confirmed the superi- 
ority of autogenous vein. More recently, the short 
longevity of the hot-tip laser exemplifies the obsoles- 
cence that befalls any vascular procedure that lacks 
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durability. Lack of durability will remain the greatest 
limitation of many current endovascular techniques. 
So what technologies have stood the test of time? 
The best example is the large-diameter Dacron poly- 
ester prosthesis for aortic replacement. This fabric 
technology fits the biologic needs and response. It 
replaces or bypasses the end-stage aneurysmal or 
occluded artery. In response to its presence, the body 
puts up a relatively innocuous immune response and 
provides remarkable tissue incorporation, especially 
on velour surfaces. Another example of a reasonably 
successful technology has been the Grfintzig balloon 
catheter for focal stenoses in larger arteries. It takes 
advantage of the distensibility of elastic arteries (e.g., 
common iliac artery) and the healing and remodeling 
capacity of the disrupted atherosclerotic plaque. 
Dacron grafts and Grtntzig balloons for larger- 
vessel disease have escaped obsolescence because 
their designers understood the reaction of the hu- 
man body to foreign bodies and injury in these ana- 
tomic locations. In contrast, biologically oriented 
surgeons have also understood the thrombogenic 
limits of synthetic grafts and angioplasty in treating 
smaller arterial occlusive lesions. Can grafts and an- 
gioplasty be improved? Of course they will evolve, 
but their fundamental designs and applications may 
not change dramatically because they integrate rea- 
sonably well now with biologic reactions and heal- 
ing. The future of better graft materials and angio- 
plasty must incorporate adjunctive biologic therapy 
that modifies coagulation and healing. 
Patient satisfaction is also linked to the durability 
of a vascular procedure. Sometimes, patients eem to 
understand urability better than their own physi- 
cians or surgeons. Recently, awoman called me from 
a small Midwestern community where she and sev- 
eral friends had undergone repetitive balloon angio- 
plasties of various cardiovascular lesions. Some of 
them had minimal improvement or rapid recurrence 
of their symptoms. Nonetheless, the cardiologist 
who was performing the procedures advised them 
that more angioplasty remained the best therapeutic 
option. The woman called to ask whether surgery 
was still being done for vascular disease. In my con- 
versation with her, she asked, "Doctor, don't you 
think that an operation might last longer? I am tired 
of these angioplasties every few months!" I assured 
her that she had reached the right telephone number. 
How much does it cost? 
Until recently, cost did not seem to hold a pivotal 
position in whether a certain procedure became ob- 
solete. Private insurance and Medicare did a reason- 
able job of covering the charges for most patients. 
With few exceptions, I did whatever I felt was best 
for the patient without worrying about costs. Occa- 
sionally an uninsured patient reminded me that vas- 
cular interventions cost more than most cars and 
some houses. I believe that cost is becoming an 
increasingly important factor in whether a vascular 
procedure ver establishes or maintains a foothold in 
the therapeutic menu. 
Let us consider the future management of ab- 
dominal aortic aneurysms. On the surface, endovas- 
cular grafting seems less expensive. But is it? Cur- 
rently, most infrarenal aortic aneurysms can be 
adequately imaged with high-resolution ultrasound 
($200 to $300). Computed tomography and aortog- 
raphy are not necessary for most cases. Total hospital 
costs for surgical repair including the prosthetic graft 
and surgeon's fee can be contained to $15,000 to 
$20,000. In contrast, the preparation for an endo- 
vascular graft requires at least one computed tomo- 
graphic scan ($500 to $1000) and an aortogram 
($2500 to $5000). The intraluminal graft and inser- 
tion kit will run $4000 to $6000 and maybe more. 
Anesthesia support, surgical fees, and hospital 
charges will add another $5000 to $15,000. In the 
end, the endovascular p ocedure may not save much 
time or money. In fact, it could cost more than 
standard surgical care. Endovascular grafts will play 
some role in the future, but randomized clinical trials 
will have to settle many current uncertainties about 
their durability and costs. 
Is it ethical to change? 
In selecting a procedure to help a patient, I al- 
ways try to steer an ethical course. But what is ethical 
when trying new therapies and discarding old ones? 
What seems unethical to me may seem perfectly al- 
right to someone lse. Medical ethics take on fuzzy 
margins in some cases. The most recent case in point 
is carotid balloon angioplasty. I never envisioned that 
any physician with an oriented mental status would 
even consider it. After all, we have a relatively simple, 
safe, and durable procedure in carotid endarterec- 
tomy. The length of hospitalization and cost have 
been reduced dramatically in recent years. So why 
change? And are we tip-toeing on the margins of 
unethical behavior? 
Every new procedure should be carefully scruti- 
nized for its ethical implications. When an effective 
procedure already exists at a reasonable cost, a new 
therapy should have a significant likelihood of im- 
proving results and lowering costs. If these advan- 
tages seem unlikely, introduction of a new proce- 
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dure, especially i f  it is associated with a potential ly 
morb id  " learning curve," is probably  not  in the pa- 
t ient's best intercst. I f  the potential  benefits o f  a new 
procedure are debatable,  carefully moni tored clinical 
trials are the only ethical solution. 
How shou ld  we pred ic t  fu ture  obsolescence? 
Each day I hear a lot  about  the future o f  medicine 
and surgery. In my opinion,  so much is speculative. 
However,  some changes appear certain. The number  
o f  elderly patients with vascular disease is going to 
increase, and some l imit on resources to care for 
them seems inevitable. One o f  my colleagues keeps 
reminding me that futurc procedures will be based 
on the outcomes o f  randomized clinical trials. I be- 
lieve this warning and agree that clinical trials remain 
the opt imal method to determine obsolescence. Af- 
ter 20 years o f  performing vascular procedures,  I also 
know that the procedures that endure have common 
characteristics that are timeless. They can be per- 
formed consistently and with relative ease by a large 
number  o f  physicians and surgeons. Their  combined 
morbid i ty  and mortal i ty rate is generally less than 5% 
to 10%, and their cost is reasonable and perhaps 
reducible in the future. And  above all, their benefits 
to the patient are durable. 8 
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